Tianjin Medical University Cancer Institute & Hospital
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China23 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors | Advanced Cancer | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-29 | NCT04495296 | |
| An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers | Advanced Solid Tumor | Enrolling by invitation | Phase 1 | 2026-09-21 | NCT06169579 | |
| A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RCZY690 in Advanced Solid Tumors | Advanced Malignant Solid Tumors | Not yet recruiting | Phase 1 / Phase 2 | 2026-09-08 | NCT07806175 | |
| A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Not yet recruiting | Phase 3 | 2026-08-31 | NCT07795346 | |
| A Phase II Trial of LM103 in Advanced Melanoma | Advanced Melanoma | Recruiting | Phase 2 | 2026-08-31 | NCT07310784 | |
| A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Liver Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, bile duct disorder, bile duct neoplasm, biliary tract disorder, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cholangiocarcinoma, digestive system disorder, digestive system neoplasm, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gastric neoplasm, liver disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, stomach disorder, uterine disorder | Recruiting | Phase 1 / Phase 2 | 2026-08-27 | NCT05150691 | |
| A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-08-11 | NCT06680921 | |
| Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer | Gastric / Gastroesophageal Junction Adenocarcinoma; MSI-H Cancer | Recruiting | Phase 2 | 2026-08-05 | NCT07127822 | |
| AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC | Resectable Non-small Cell Lung Cancer | Active, not recruiting | Phase 2 | 2026-07-29 | NCT05247684 | |
| Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal Cancer | colorectal adenocarcinoma | Not yet recruiting | Phase 2 | 2026-07-09 | NCT07691632 | |
| A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer | Advanced Prostate Cancer | Recruiting | Phase 1 / Phase 2 | 2026-06-02 | NCT07198633 | |
| A Pan-Cancer Retrospective Study on the Relationship Between Tumor Microenvironment Composition and Efficacy of Antibody-Based Antitumor Therapy | Antibody; Tumor Microenvironment | Active, not recruiting | Not stated | 2026-05-13 | NCT07584044 | |
| A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC | Extrapulmonary Neuroendocrine Carcinoma; Large-Cell Neuroendocrine Carcinoma of the Lung | Not yet recruiting | Phase 2 | 2026-04-03 | NCT07510594 | |
| Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal disorder, esophageal squamous cell carcinoma, neoplasm, squamous cell carcinoma, squamous cell neoplasm | Recruiting | Phase 2 | 2026-03-11 | NCT07457528 | |
| A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC. | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 1 / Phase 2 | 2026-02-10 | NCT06064812 | |
| A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-02-05 | NCT02763566 | |
| A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2025-06-10 | NCT05346224 | |
| Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2025-05-13 | NCT05294055 | |
| A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Recruiting | Phase 1 | 2025-04-06 | NCT06914037 | |
| Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Recruiting | Phase 2 | 2025-02-07 | NCT04586478 | |
| A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid Tumors | Mesothelin Positive Tumors | Recruiting | Not applicable | 2024-12-04 | NCT06717022 | |
| HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, endometrium neoplasm, fallopian tube cancer, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, primary peritoneal carcinoma, uterine disorder | Recruiting | Phase 2 | 2024-08-29 | NCT06014190 | |
| Goal-directed Enteral Nutritional Perioperative Management | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, Nutritional and Metabolic Diseases, digestive system disorder, digestive system neoplasm, esophageal cancer, esophageal disorder, neoplasm, nutritional deficiency disease, nutritional disorder | Recruiting | Not applicable | 2024-07-19 | NCT06510543 |